Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive lipid accumulation (steatosis) in >5% of hepatocytes without significant alcohol consumption or secondary causes. It ranges from benign isolated steatosis (NAFL) to Non-Alcoholic Steatohepatitis (NASH), which involves lobular inflammation and hepatocyte ballooning, potentially progressing to cirrhosis and hepatocellular carcinoma.

NAFLD is primarily driven by caloric excess, metabolic syndrome, and insulin resistance. Genetic polymorphisms (e.g., PNPLA3, TM6SF2) significantly increase susceptibility. Secondary causes, such as rapid weight loss, lipodystrophy, and medications (e.g., amiodarone, tamoxifen, corticosteroids), can also induce hepatic steatosis.

Caloric overload and insulin resistance increase peripheral adipose tissue lipolysis, delivering excess free fatty acids (FFAs) to the liver. This stimulates hepatic de novo lipogenesis and impairs beta-oxidation, resulting in triglyceride accumulation within hepatocytes. Chronic lipotoxicity triggers mitochondrial dysfunction, endoplasmic reticulum stress, and oxidative stress. This activates inflammatory pathways (NF-κB) and hepatic stellate cells, driving progressive collagen deposition and fibrosis.

• Global Prevalence: Approximately 25% to 30% of the adult population.
• Demographics: Higher prevalence in Hispanic populations; lowest in African American populations. Prevalence increases with age and is slightly higher in males.
• Comorbidities: Affects up to 70% of individuals with Type 2 Diabetes and 90% of those with severe obesity.

• Obesity (especially visceral adiposity)
• Type 2 Diabetes Mellitus
• Atherogenic Dyslipidemia (high triglycerides, low HDL-C)
• Metabolic Syndrome
• Polycystic Ovary Syndrome (PCOS)
• Hypothyroidism
• Obstructive Sleep Apnea

• Early/Uncomplicated: Often completely normal. Mild hepatomegaly may be palpable.
• Advanced Disease (Cirrhosis): Scleral icterus, splenomegaly, ascites, palmar erythema, spider angiomas, caput medusae, muscle wasting, and asterixis.

Alanine Aminotransferase (ALT)

• Type: Blood Test


• Purpose: Screening for active hepatocellular injury.


• Expected Findings: Mildly elevated (often ALT > AST in early stages).


• Interpretation: Marker of necroinflammatory activity; normal levels do not exclude advanced fibrosis. FIB-4 Index


• Type: Serum calculation (Age, AST, ALT, Platelets)


• Purpose: Non-invasive assessment of hepatic fibrosis risk.


• Expected Findings: Score <1.3 (low risk) or >2.67 (high risk of advanced fibrosis).


• Interpretation: Guides clinical pathways for specialist referral or biopsy.

• Abdominal Ultrasound: Primary screening tool. Reveals increased echogenicity ("bright liver") with posterior acoustic attenuation. It is non-invasive but insensitive to steatosis <20%.
• Vibration-Controlled Transient Elastography (FibroScan): Measures liver stiffness (elasticity in kPa) and Controlled Attenuation Parameter (CAP). It differentiates mild from advanced fibrosis and quantifies steatosis.

• Alcoholic Liver Disease (ALD): Distinguished by a history of significant alcohol consumption (>20g/day for women, >30g/day for men) and an AST:ALT ratio > 2:1.
• Chronic Hepatitis C: Confirmed by positive HCV antibody and HCV RNA assays.

• Hepatic Cirrhosis
• Portal Hypertension (ascites, varices, splenomegaly)
• Hepatic Encephalopathy
• Hepatocellular Carcinoma (HCC)
• Cardiovascular Disease (leading cause of mortality in NAFLD patients)

Simple steatosis is generally benign. However, NASH carries a 15-25% risk of progressing to cirrhosis over 10-20 years. The presence and severity of hepatic fibrosis are the strongest predictors of all-cause and liver-related mortality.

Primary prevention centers on preventing obesity through a balanced diet, regular physical activity, and early metabolic screening.

The following homeopathic remedies have been historically indicated for symptoms associated with Non-Alcoholic Fatty Liver Disease. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Liver Function & Fibrosis Analyzer

Comprehensive multi-metric clinical liver analyzer. Simultaneously evaluates AST, ALT, Platelets to compute De Ritis Ratio, APRI Score, and FIB-4 Index for fibrosis staging.